A Phase 3 interventional study of Cariprazine and Antidepressant Therapy (ADT) in Major Depressive Disorder, sponsored by Forest Laboratories. Completed at 90 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-21.
Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.
Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 26th largest by enrollment, is one of 2 that started in 2013, is one of 31 in phase 3, and was the 26th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:
AbbVie · Sites in United States
Ages 18–65
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 442 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 442 across the 53 interventional studies. Of the 50 that completed or were terminated, 37 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Forest Laboratories, one of the names counted as AbbVie. Under that name alone:
Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
1 of the studies in Depressive Disorder, Major by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07276997AbbVieA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies in Depressive Disorder, Major by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cariprazine, flexible dose (titrated to a dose of 3.0 milligrams (mg) adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability), oral administration, once daily plus antidepressant drug therapy (ADT) for 26 weeks.
Drug: Cariprazine · Drug: Antidepressant Therapy (ADT)
Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.
Time frame: First dose of study drug to last dose of study drug in the 26-week Treatment Period and within 30 days of last dose of study drug for participants who did not participate in the 2-week Safety Follow-up Period (Up to 30 weeks)
Number of Participants With Newly Emergent Adverse Events (NEAEs) in the Safety Follow-up Period
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A NEAE is a new AE that occurred during the 2-week Safety Follow-up Period.
Time frame: 2 weeks following the 26-week Treatment Period
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters
Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.
Time frame: Baseline (Week 0) to up to 26 weeks in the Treatment Period
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters
Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.
Time frame: Baseline (Week 0) to up to 26 weeks in the Treatment Period plus a 2-week Safety Follow-up Period (Up to 28 weeks)
Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)
A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.
Time frame: Baseline (Week 0) to up to 26 weeks
Number of Participants With Extrapyramidal Symptom (EPS)-Related TEAEs
Extrapyramidal symptoms are drug-induced movement disorders such as dystonia, akathisia, parkinsonism, bradykinesia, tremor, and tardive dyskinesia.
Time frame: First dose of study drug to last dose of study drug in the 26-week Treatment Period plus a 2-week Safety Follow-up Period or within 30 days of last dose of study drug for participants who did not participate in the Safety Follow-up Period (Up to 30 weeks)
Number of Participants in the Most Severe Suicidal Ideation and Suicidal Behavior Recorded on the C-SSRS During the Treatment Period
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent). The C-SSRS also captures information about the intensity of ideation, specifically the frequency, duration, controllability, deterrents, and reasons for the most severe types of ideation. Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior to 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes.
Time frame: Baseline (Lead-in study Baseline for roll-over participants and prior to first dose in this study for new participants) to Week 26 in this study
Number of Participants With Treatment-Emergent Ocular Events
A TEAE is an AE that occurs or worsens after receiving study drug. Ocular events are adverse events related to the eye.
Time frame: First dose of study drug to last dose of study drug in the 26-week Treatment Period plus a 2-week Safety Follow-up Period or within 30 days of last dose of study drug for participants who did not participate in the Safety Follow-up Period (Up to 30 weeks)
Change From Baseline in the Arizona Sexual Experiences Scale (ASEX) Score
The ASEX is a participant-completed scale to evaluate overall sexual experiences over the previous 7 days consisting of 5 questions answered on a scale of 1 (best) to 6 (worst) for a total possible score of 3 to 30 (2 questions were only answered if the participant was sexually active in the past week), higher score indicates greater sexual dysfunction. There are different forms for males and females. A negative change from Baseline indicates improvement.
Time frame: Baseline (Lead-in study Baseline for roll-over participants and prior to first dose of this study for new participants) to End of Treatment (Up to Week 26) in this study
| Milestone | Cariprazine + ADT |
|---|---|
| Started | 442 |
| Safety population; received study drug | 345 |
| Entered safety follow-up period | 287 |
| Completed | 209 |
| Not completed | 233 |
| Withdrew: Adverse event | 49 |
| Withdrew: Insufficient therapeutic response | 10 |
| Withdrew: Protocol violation | 34 |
| Withdrew: Withdrawal of consent | 33 |
| Withdrew: Lost to follow-up | 21 |
| Withdrew: Study or site terminated by sponsor | 1 |
| Withdrew: Reason not specified | 7 |
| Withdrew: Did not meet eligibility criteria | 78 |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.
| Participants | Cariprazine + ADT |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period | 274 |
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A NEAE is a new AE that occurred during the 2-week Safety Follow-up Period.
| Participants | Cariprazine + ADT |
|---|---|
| Number of Participants With Newly Emergent Adverse Events (NEAEs) in the Safety Follow-up Period | 20 |
Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.
| Participants | Cariprazine + ADT |
|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters | 0 |
Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.
| Participants | Cariprazine + ADT |
|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters | 0 |
A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.
| Participants | Cariprazine + ADT |
|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG) | 1 |
Extrapyramidal symptoms are drug-induced movement disorders such as dystonia, akathisia, parkinsonism, bradykinesia, tremor, and tardive dyskinesia.
| Participants | Cariprazine + ADT |
|---|---|
| Number of Participants With Extrapyramidal Symptom (EPS)-Related TEAEs | 98 |
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent). The C-SSRS also captures information about the intensity of ideation, specifically the frequency, duration, controllability, deterrents, and reasons for the most severe types of ideation. Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior to 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes.
| participants | Cariprazine + ADT |
|---|---|
| No Suicidal Ideation | 308 |
| Suicidal Ideation | 37 |
| Suicidal Ideation with Specific Plan and Intent | 1 |
| Ideation,Some Intent to Act,without Specific Plan | 0 |
| Ideation,any Methods,without Intent to Act | 6 |
| Non-specific Active Suicidal Thoughts | 3 |
| Wish to be Dead | 27 |
| No Suicidal Behavior | 344 |
| Suicidal Behavior | 1 |
| Completed Suicide | 0 |
| Actual Suicide Attempt | 1 |
A TEAE is an AE that occurs or worsens after receiving study drug. Ocular events are adverse events related to the eye.
| Participants | Cariprazine + ADT |
|---|---|
| Number of Participants With Treatment-Emergent Ocular Events | 1 |
The ASEX is a participant-completed scale to evaluate overall sexual experiences over the previous 7 days consisting of 5 questions answered on a scale of 1 (best) to 6 (worst) for a total possible score of 3 to 30 (2 questions were only answered if the participant was sexually active in the past week), higher score indicates greater sexual dysfunction. There are different forms for males and females. A negative change from Baseline indicates improvement.
| score on a scale | Cariprazine + ADT (Female) | Cariprazine + ADT (Male) |
|---|---|---|
| Baseline | 20.1 ± 5.9 | 17.2 ± 5.5 |
| Change from Baseline to the End of Treatment | -0.9 ± 4.4 | -0.1 ± 4.6 |
Collected over First dose of study drug to last dose of study drug in the 26-week Treatment Period plus a 2-week Safety Follow-up Period or within 30 days of last dose of study drug for participants who did not participate in the Safety Follow-up Period (Up to 30 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cariprazine + ADT | 2/345 (0.6%) | 7/345 (2%) | 274/345 (79.4%) |
| Event | Cariprazine + ADT |
|---|---|
| Blood creatine phosphokinase increasedInvestigations | 1/345 |
| Completed suicidePsychiatric disorders | 1/345 |
| FallInjury, poisoning and procedural complications | 1/345 |
| PneumoniaInfections and infestations | 1/345 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/345 |
| Spinal cord injuryInjury, poisoning and procedural complications | 1/345 |
| Substance-induced psychotic disorderPsychiatric disorders | 1/345 |
| Suicide attemptPsychiatric disorders | 1/345 |
| Event | Cariprazine + ADT |
|---|---|
| AkathisiaNervous system disorders | 55/345 |
| HeadacheNervous system disorders | 40/345 |
| Weight increasedInvestigations | 34/345 |
| AnxietyPsychiatric disorders | 34/345 |
| InsomniaPsychiatric disorders | 34/345 |
| RestlessnessPsychiatric disorders | 34/345 |
| FatigueGeneral disorders | 30/345 |
| NasopharyngitisInfections and infestations | 30/345 |
| NauseaGastrointestinal disorders | 21/345 |
| DizzinessNervous system disorders | 20/345 |
Safety Population included all participants in the enrolled population who took at least 1 dose of cariprazine in this study.
| Age, Continuous(years) | Cariprazine + ADT |
|---|---|
| Mean | 46.7 ± 10.5 |
| Sex: Female, Male(Participants) | Cariprazine + ADT |
|---|---|
| Female | 249 |
| Male | 96 |
| Race/Ethnicity, Customized(Participants) | Cariprazine + ADT |
|---|---|
| Race — White | 280 |
| Race — Black or African American | 54 |
| Race — Asian | 6 |
| Race — American Indian or Alaska Native | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 1 |
| Race — Other | 3 |
| Race/Ethnicity, Customized(Participants) | Cariprazine + ADT |
|---|---|
| Ethnicity — Hispanic or Latino | 75 |
| Ethnicity — Non-Hispanic or Latino | 270 |
Ran from Apr 2013 to primary completion in Jul 2015, 26 months.
Results were first posted in Aug 2019, 4 years after primary completion. A results delay was requested in Aug 2016.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 26 months is close to that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cariprazine